Crisaborole

Crisaborole is a topical medication used for the treatment of mild to moderate atopic dermatitis, commonly known as eczema. It is a phosphodiesterase-4 (PDE4) inhibitor, a class of drugs that work by reducing inflammation in the skin. PDE4 is an enzyme involved in the inflammatory pathways, and by inhibiting it, crisaborole helps to decrease the release of cytokines and other inflammatory mediators that contribute to the symptoms of eczema, such as itching and redness.

The drug is available as an ointment and is applied directly to the affected areas of the skin. It is generally well-tolerated, with the most common side effect being a burning or stinging sensation at the application site. Other less common side effects can include redness, itching, and rash. Crisaborole is not a corticosteroid, which is a common treatment for eczema, and this can be an advantage for individuals seeking non-steroidal options, especially for long-term use or in sensitive areas.

Clinical trials have demonstrated that crisaborole can effectively reduce the signs and symptoms of atopic dermatitis, including pruritus (itching) and erythema (redness). It is typically prescribed for patients who have not responded adequately to other topical treatments or for whom topical corticosteroids are not recommended. The mechanism of action of crisaborole, targeting PDE4, is distinct from other topical eczema treatments, offering a different therapeutic approach. It is important for patients to use crisaborole as directed by their healthcare provider and to report any persistent or bothersome side effects.